CDSCO (India)
NOTICE
Manufacturing and marketing of unapproved drug product Sodium Hyaluronate Eye Drops 0.3% w/v
Published: 3/18/2026Detected: 3/19/2026
Summary preview
Clarifies the regulatory stance on the manufacturing and marketing of Sodium Hyaluronate Eye Drops 0.3% w/v, categorizing them as unapproved products under current law.
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountophthalmology
manufacturing
quality
safety
#Sodium Hyaluronate
#eye drops
#unapproved drugs
#manufacturing compliance
#quality assurance
Official Source Document Source Verified
Access the original document directly from INDIA CDSCO.
More from CDSCO (India)
- 28.10.2026 G.S.R. 954(E)_Draftâ Amendment of Rule 43A of the Drugs Rules, 1945 to include various ICDs/Port/SEZs for the import of Drugs/ Medical Devices/ Cosmetics in India10/28/2026
- 28.10.2026 G.S.R. 955(E)_Draft Notification for amendment in the Drugs Rules, 1945 for requirement of an authorised person responsible for batch release of product10/28/2026
- 2026.10.28 G.S.R. 951(E)_Notification regarding rationalization of shelf life under Rule 31 of Drugs Rules, 194510/28/2026
- Appointment of Central Compounding Authority Order10/28/2026
- Misleading or false claims of the product FatX solution registered under COS-2 vide RC no. RC/COS-003300 by the firm M/s Tekno Midas Aesthetics10/28/2026